Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant, is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. Our earlier-stage product candidate, OP-3136, is a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. We are headquartered in San Francisco and have operations in Cambridge, Massachusetts. If you're interested in joining Team Olema, learn more about who we are, what we do, and how we do it at www.olema.com. Important Notice: Fraudulent Recruiting Activities We are aware of employment scams where individuals pose as representatives of Olema Oncology and make false use of our company name to defraud job seekers.
- Founded
- 2007
- Company size
- 51-200
- Headquarters
- San Francisco, California, US
- Funding
- Post Ipo Equity
Hiring activity
- Open roles
- 11
- Posted in the last 30 days
- 17
- Most common roles
- Supply Chain ManagerCompliance OfficerQA Engineer
Updated 8h ago
Latest openings
11 open roles at Olema Oncology. Members see each one.